What is a pharmacogenomics association study? And why do we need standards?
Pharmacogenomics association studies decisively influence the innovation path from gene discovery on the bench-side to the commercially available genetic test in the clinic. Pharmacogenomics association studies have thus a dual impact on prioritizing basic genomics discoveries (e.g., focusing bench research on certain candidate genes) as well as translational medicine. There are three essential components of a pharmacogenomics association study. These include: (1) the molecular genetic analysis of person-to-person differences in the human genome, (2) the ascertainment of pharmacological phenotypes (e.g., measurement of drug response and side effects) and, (3) the bioinformatics analysis to evaluate the relationship between (1) and (2); i.e., genome-phenotype statistical association analysis. The pharmacogenomics association studies are rapidly proliferating in the bioscience literature. With the decreasing costs of genotyping, it is anticipated that this trend will accelerate further i
